Skip to content

Jeff Sutherland

Twice the Energy with Half the Stress

Cancer Frequencies: Finally a Clinical Trial

We’ve known for decades that frequencies are an excellent approach to treating cancer with dramatically less side effects than chemotherapy and radiation. It is nice to finally see a group do a successful clinical trial on this.

This team did not even use frequencies in the range known to kill cancer cells and were successful. Image what they could if they utilized the expertise in the worldwide community working with this technology!

An important finding (pointed out for many years on this site) is that frequencies are specific to specific cells and cell types. This makes it challenging for the average university research groups. As Rife has shown us, getting the exact frequencies requires painstaking work for many years with highly refined tools not generally available. 

Also well known, and can be inferred by the data in this study, is that it is difficult to eliminate cancer completely for terminal cases, but possible to signficantly increase the life span and quality of life compared to conventional treatment. 

Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach
Alexandre Barbault, Frederico P Costa , Brad Bottger , Reginald F Munden , Fin Bomholt , Niels Kuster  and Boris Pasche
Cabinet Médical, Avenue de la Gare 6, Lausanne, Switzerland
Rue de Verdun 20, Colmar, FranceSirio-Libanes Hospital, Oncology Center, São Paulo, Brazil
Radiology Associates, Danbury Hospital, Danbury, CT, USA
5Department of Radiology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL, USA
SPEAG AG, Zurich, Switzerland
IT’IS, Swiss Federal Institute of Technology, Zurich, Switzerland
Division of Hematology/Oncology, Department of Medicine, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL, USA

Journal of Experimental & Clinical Cancer Research 2009, 28:51doi:10.1186/1756-9966-28-51

The electronic version of this article is the complete one and can be found online at:

Received:    8 January 2009
Accepted:    14 April 2009
Published:    14 April 2009
© 2009 Barbault et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer.

Patients and methods
We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options.

We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57–92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver).

Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer.

Trial registration identifier NCT00805337